MRNY ETF Delivers +152% Gain in 30 Days on Moderna (MRNA) Catalyst

Key Takeaways

• MRNY gained roughly 152% over the trailing 30 days, with nearly all of that advance occurring in a single session following a landmark clinical catalyst for Moderna (MRNA).
• The fund is an actively managed single-stock covered-call strategy, meaning its upside participation in MRNA is capped relative to the underlying stock's move.
• Over the trailing quarter the ETF rose approximately 140%, but virtually the entire gain was concentrated in the final week of the period.
• The primary driver was positive Phase 3 data for Moderna and Merck's (MRK) personalized mRNA melanoma vaccine, amplified by a heavy short squeeze in MRNA shares.
• MRNY's income-oriented structure, weekly distributions, and 1.00% expense ratio distinguish it from a direct position in the underlying stock.

Overview of the MRNY ETF and Its Strategy

The YieldMax MRNA Option Income Strategy ETF (MRNY) is an actively managed, non-diversified derivative income fund that seeks current income as its primary objective and capped exposure to the share price of Moderna, Inc. as a secondary objective. Rather than owning MRNA shares directly, the fund uses a synthetic covered-call (call spread) strategy, selling call options on MRNA while holding a collateralized position in cash and U.S. Treasury bills.

The portfolio typically holds roughly 15 to 18 securities, dominated by short-dated U.S. Treasury bills, cash-equivalent vehicles, and MRNA options positions rather than equity holdings. This structure directly shapes performance: MRNY collects option premium and distributes income weekly, but the short call positions limit how much of MRNA's upside the fund can capture during sharp rallies. The fund carries a gross expense ratio of 1.00% and was launched in October 2023. I also checked this using Tickeron’s AI Screener to see how the fund compares to other single-stock option income vehicles.

MRNY's Price Performance Over the Past 30 Days and Quarter

MRNY's recent price action was anything but gradual. The ETF closed near $14.65 roughly 30 days prior and finished the period near $36.97, a gain of approximately 152%. Over the trailing quarter, the fund advanced roughly 140% from a reference level near $15.42.

Critically, the shape of that move matters more than the headline figure. Through July and the first half of August, MRNY drifted lower from the low-$20s toward the mid-$14s, trading in a volatile but broadly range-bound pattern as MRNA shares weakened. The entire repricing occurred on a single day in mid-August, when MRNY surged roughly 169% in one session and subsequently oscillated in a wide $30-to-$42 band as traders reassessed the fund's capped upside.

Key Driver of the Recent 30-Day Rally

The overwhelming driver of MRNY's 30-day surge was a single event in Moderna's oncology pipeline. Moderna and Merck announced that their personalized mRNA cancer vaccine, evaluated in combination with Merck's immunotherapy Keytruda, met its primary endpoints in a Phase 3 trial for high-risk melanoma. The result marked the first late-stage success for an mRNA-based individualized cancer therapy and validated the broader mRNA oncology platform.

MRNA shares soared roughly 177% in one session, climbing from about $63 to approximately $174, before settling back and then rebounding to near $159. The scale of the move was magnified by positioning: short interest in MRNA had been estimated in the low double digits of the company's float, and the scramble to cover bearish bets created a powerful short squeeze. Merck shares also rose by roughly 10% to 12% on the news.

Because MRNY sells call options on MRNA, its roughly 169% single-session gain slightly lagged the underlying stock's move, reflecting the capped participation built into the fund's design. A wave of analyst price-target upgrades across major financial institutions followed the data release, reinforcing the repricing of the underlying equity.

Quarter Performance in Context

For most of the quarter, the environment was far less favorable. Moderna entered the period under pressure from a post-pandemic decline in COVID-19 vaccine revenue and uncertainty around its pipeline, which kept MRNA in a downtrend and left MRNY trading in a choppy $14-to-$21 range. Option premiums and weekly distributions provided income to holders, but the underlying share-price weakness limited capital appreciation.

The quarter's roughly 140% gain is therefore almost entirely attributable to the final-week catalyst rather than a sustained sector rotation. This concentration underscores a defining feature of single-underlying derivative income funds: returns are binary and event-driven, dominated by the fortunes of one issuer rather than by broad market or industry trends.

Outlook for MRNY and What to Monitor

Going forward, MRNY's trajectory will remain tied to Moderna's ability to convert clinical momentum into commercial and regulatory milestones. The full trial dataset, including the recurrence-free survival hazard ratio, is expected to be presented at a major medical conference in late October, and investors will watch whether the detailed results support the initial topline enthusiasm.

Regulatory discussions and a potential approval timeline—management has indicated a possible path toward approval as early as 2027—represent the next key catalysts. Meanwhile, Moderna remains unprofitable, and its share price now reflects substantial optimism, leaving the stock vulnerable to profit-taking and volatility. I’m watching this closely because future gains in MRNA will not translate one-for-one into ETF performance given the capped structure.

Exploring Opportunities with Tickeron’s AI Screener

In my own research, Tickeron’s AI Screener has become a useful tool for scanning single-stock option income ETFs and related biotech names by technical indicators, fundamentals, volatility, and performance metrics. It helps surface candidates that align with specific strategies like income generation or event-driven exposure without requiring hours of manual filtering.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Jimmy Landsman|Expert

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.

Industry description